睿知中国医院研究地图
候选清单

北京北京大学医学部

北京大学第三医院

Peking University Third Hospital

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

北京大学第三医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma11 篇牵头论文牵头 1 项开放试验
  2. 胃癌Stomach cancer24 篇牵头论文牵头 2 项开放试验
  3. 脊索瘤Chordoma6 篇牵头论文
  4. 骨肉瘤Osteosarcoma7 篇牵头论文
  5. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  6. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  10. β 地中海贫血Beta thalassaemia0 篇牵头论文
  11. 血友病 AHaemophilia A1 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  13. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
  14. IgG4相关性疾病IgG4-related disease2 篇牵头论文
  15. 烟雾病Moyamoya disease2 篇牵头论文
  16. 大动脉炎Takayasu arteritis1 篇牵头论文
  17. 肝包虫病Hepatic echinococcosis0 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis52 篇牵头论文牵头 2 项开放试验
  20. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文牵头 1 项开放试验
  21. 法布雷病Fabry disease1 篇牵头论文
  22. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  23. 白塞病Behçet disease0 篇牵头论文
  24. IgA 肾病IgA nephropathy1 篇牵头论文
  25. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  26. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、范可尼贫血、重症肌无力、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肺淋巴管平滑肌瘤病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.07%。

牵头论文
11
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 4420242025: 332025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07760012

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学第三医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物放疗
论文中的科室放疗科普外/肝胆胰外科消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文11
  1. Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.2025BMC cancer免费全文
  2. Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation.2025Molecular cancer免费全文
  3. Stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.2025Radiation oncology (London, England)免费全文
  4. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.2024Biomolecules免费全文
  5. Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.2024Cancer medicine免费全文
  6. CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker.2024Scientific reports免费全文
  7. Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma.2024World journal of surgical oncology免费全文
  8. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Allosteric regulation of the lid domain of PCK2 as a novel strategy for modulating mitochondrial dynamics.2023Chemical communications (Cambridge, England)
  10. Advances in radiotherapy and immunity in hepatocellular carcinoma.2023Journal of translational medicine免费全文
  11. Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.2022Clinics and research in hepatology and gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors正在招募NCT07760012牵头方不分期2026-08 启动
  2. Assessment of Remnant Liver Function in ALPPS by Gd-EOB-DTPA Enhanced MRI状态不明NCT04559451牵头方2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.2%。

牵头论文
24
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 9920222023: 4420232024: 3320242025: 662025

北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
    分期
    II期
    开始
    2023-04
    登记号
    NCT06792162

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学第三医院北京

  2. 即将招募
    Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
    分期
    不分期
    开始
    2019-03
    登记号
    NCT03857737

    年龄未注明(登记的条件)

    牵头:北京大学第三医院北京

  3. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  4. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜免疫与靶向药物影像与人工智能
论文中的科室消化/肝病科影像/核医学科普外/肝胆胰外科病理/检验科
牵头的论文24
  1. Helicobacter pylori infection status and evolution of gastric cancer.2025Chinese medical journal免费全文
  2. Dynamic changes of host immune response during Helicobacter pylori-induced gastric cancer development.2025Clinical and experimental immunology
  3. Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.2025International journal of biological sciences免费全文
  4. Ultrasound-triggered topical oxygen delivery enhances synergistic sonodynamic and antibody therapies against hypoxic gastric cancer.2025Journal of controlled release : official journal of the Controlled Release Society
  5. Cmtm4 Deficiency Inhibits Helicobacter pylori-Induced Gastric Carcinogenesis.2025Pathology international
  6. Raman spectroscopy and machine learning for early detection of gastric cancer and Helicobacter pylori with gastric juice.2025Scientific reports免费全文
  7. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  8. Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-κB/IL8 pathway.2024Helicobacter
  9. Machine learning models to predict submucosal invasion in early gastric cancer based on endoscopy features and standardized color metrics.2024Scientific reports免费全文
  10. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Long-term outcomes of additional surgery versus non-gastrectomy treatment for early gastric cancer after non-curative endoscopic submucosal dissection: a meta-analysis.2023Chinese medical journal免费全文
  12. The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.2023Helicobacter
  13. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.2023Phytotherapy research : PTR
  14. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.2022ACS applied materials & interfaces
  15. Double contrast-enhanced ultrasound for the preoperative gross classification of gastric cancer: a comparison with multidetector computed tomography.2022BMC medical imaging免费全文
  16. Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.2022Biochimica et biophysica acta. Gene regulatory mechanisms
  17. Traditional Chinese medicine for precancerous lesions of gastric cancer: A review.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. Long-Term Outcome of Gastric Mild-Moderate Dysplasia: A Real-World Clinical Experience.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  19. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.2022Frontiers in immunology免费全文
  20. Effect of Helicobacter pylori on immunotherapy is gaining more attention.2022Helicobacter
  21. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.2022Helicobacter
  22. Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers.2022World journal of gastroenterology免费全文
  23. Downregulation of FABP5 Suppresses the Proliferation and Induces the Apoptosis of Gastric Cancer Cells Through the Hippo Signaling Pathway.2021DNA and cell biology
  24. Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis.2021Journal of gastroenterology and hepatology
中文论文(未计入)1
  1. [Analysis of endoscopic and pathological features of gastric adenomatous polyps and risk factors for canceration].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer正在招募NCT06792162牵头方II期2023-04 启动
  2. Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer即将招募NCT03857737牵头方不分期2019-03 启动
  3. Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD状态不明NCT03492827牵头方不分期2017-06 启动
  4. Predictive Factors for Roux Stasis Syndrome已完成NCT04919577牵头方2014-03 启动
  5. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  6. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  7. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  8. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  9. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  12. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer状态不明NCT04139135研究中心III期2019-12 启动
  13. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 5.7%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 3320242025: 222025

北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科影像/核医学科
牵头的论文6
  1. Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality.2025International journal of medical sciences
  2. SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.2025Scientific reports
  3. Misdiagnosis of primary dumbbell chordoma of the cervical spine.2024Asia-Pacific journal of clinical oncology
  4. Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.2024BMC musculoskeletal disorders
  5. Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma.2024Spine
  6. Preliminary study of monoexponential, biexponential, and stretched-exponential models of diffusion-weighted MRI and diffusion kurtosis imaging on differential diagnosis of spinal metastases and chordoma.2022European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
早期论文(2016–2020 年)9
  1. Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.2020Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.2020Journal of applied clinical medical physics
  3. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.2020Oncogene
  4. [Anesthesia management of cervical chordoma resection: A case report].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  5. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.2019Cancer science
  6. A brief review of chordomas: pathogenesis, prognostic factors and therapeutic targets.2019Histology and histopathology
  7. Radiofrequency ablation in gross total excision of cervical chordoma: ideas and technique.2018European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  8. Prognostic Factors in Surgical Patients with Chordomas of the Cervical Spine: A Study of 52 Cases from a Single Institution.2017Annals of surgical oncology
  9. Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the Axial Skeleton.2017Journal of magnetic resonance imaging : JMRI

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 3320242025: 002025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Arnicolide D Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells through PI3K/Akt/mTOR Pathway.2024Anti-cancer agents in medicinal chemistry
  2. Metabolic Landscape of Osteosarcoma: Reprogramming of Lactic Acid Metabolism and Metabolic Communication.2024Frontiers in bioscience (Landmark edition)
  3. Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.2024Scientific reports
  4. The Dilemma of Balance between Benefits and Losses for Chondromyxoid Fibroma-like Osteosarcoma in Thoracic Spine with Azygos Tumor Thrombosis: A Case Report.2023Medicina (Kaunas, Lithuania)
  5. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.2022Oxidative medicine and cellular longevity
  6. D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy.2021Biomaterials
  7. VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.2021Journal of materials chemistry. B
中文论文(未计入)1
  1. [Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
早期论文(2016–2020 年)9
  1. HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.2020ACS applied materials & interfaces
  2. Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.2020Journal of applied clinical medical physics
  3. Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.2019Phytotherapy research : PTR
  4. Cross Talk Between Autophagy and Apoptosis Contributes to ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death.2018Advanced healthcare materials
  5. Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.2018Cancer chemotherapy and pharmacology
  6. Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  7. Recurrence Factors in Giant Cell Tumors of the Spine.2017Chinese medical journal
  8. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.2016PloS one
  9. Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.2016Spine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Advances in the clinicopathological research of undifferentiated and dedifferentiated endometrial carcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
早期论文(2016–2020 年)3
  1. Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.2016PloS one
  3. Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.2016Spine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Anlotinib and Irinotecan for Ewing Sarcoma状态不明NCT03416517研究中心I/II期2018-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 0020232024: 0020242025: 112025

北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05565807

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

  3. 正在招募
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    分期
    IV期
    开始
    2023-10
    登记号
    NCT06057402

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、广州、杭州、济南

  4. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  5. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  6. 正在招募
    A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2022-08
    登记号
    NCT05299424

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  7. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  8. 正在招募
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2021-02
    登记号
    NCT04634552

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安

  9. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  10. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层肾脏与骨骼并发症
论文中的科室影像/核医学科
牵头的论文5
  1. Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model-Informed Precision Dosing for Chinese Population With Renal Insufficiency.2025CPT: pharmacometrics & systems pharmacology免费全文
  2. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).2022Annals of hematology免费全文
  3. Vertebral MRI-based radiomics model to differentiate multiple myeloma from metastases: influence of features number on logistic regression model performance.2022European radiology
  4. Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.2021Journal of magnetic resonance imaging : JMRI
  5. A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.2021La Radiologia medica
中文论文(未计入)2
  1. [The Pathogenesis and Treatment Progress of Extramedullary Multiple Myeloma --Review].2025Zhongguo shi yan xue ye xue za zhi
  2. [Detection of cytogenetic abnormalities in multiple myeloma by using optical genome mapping].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)32
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)正在招募NCT06057402研究中心IV期2023-10 启动
  3. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma正在招募NCT05565807研究中心I/II期2023-02 启动
  4. A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT05299424研究中心I/II期2022-08 启动
  5. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  6. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  7. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma正在招募NCT05294055研究中心II期2022-04 启动
  8. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  9. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT04634552研究中心II期2021-02 启动
  10. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  11. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  12. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  13. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  14. Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma状态不明NCT04818372研究中心I期2021-04 启动
  15. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  16. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  17. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  18. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  19. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma已完成NCT04121260研究中心I期2019-12 启动
  20. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  21. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  22. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  23. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  24. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  25. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  26. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  27. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  28. Ixazomib Rollover Study已完成NCT02924272研究中心II期2016-12 启动
  29. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动
  30. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  31. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  32. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

北京有 10 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  2. 正在招募
    Phase Ib Clinical Study of Keynatinib
    分期
    I期
    开始
    2020-09
    登记号
    NCT04807881

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 10 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Analysis of Thalassemia Gene Variants in the Wuhan Region].2025Zhongguo shi yan xue ye xue za zhi

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
牵头的论文1
  1. Single-cell whole-genome sequencing, haplotype analysis in prenatal diagnosis of monogenic diseases.2023Life science alliance
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers已完成NCT03380780研究中心I期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断孕期、儿童与老人
论文中的科室神经内科
牵头的论文2
  1. Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.2025Cell reports
  2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
PubMed 以外找到的论文(未计入)1
  1. The clinical characteristics of neuromyelitis optica spectrum disorders with other autoimmune diseases2022DOAJ (DOAJ: Directory of Open Access Journals)论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题治疗与复发诊断与鉴别
论文中的科室风湿免疫科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

北京有 8 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题遗传影像与脑血流
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科影像/核医学科
牵头的论文1
  1. The performance of the 2022 ACR/EULAR classification criteria for Takayasu's arteritis as compared to the 1990 ACR classification criteria in a Chinese population.2023Clinical and experimental medicine
中文论文(未计入)1
  1. [Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
早期论文(2016–2020 年)1
  1. [Anesthesia management of caesarean section for pregnant women complicated with Takayasu's arteritis].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 6 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Management of Advanced Hepatic Alveolar Echinococcosis: Report of 42 Cases.2017The American journal of tropical medicine and hygiene

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 52 篇,占 6.7%。

牵头论文
52
2021–2025 年
牵头试验
21
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 111120222023: 5520232024: 6620242025: 14142025

北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
    分期
    IV期
    开始
    2023-01
    登记号
    NCT05923905

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:北京大学第三医院北京

  2. 正在招募
    Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
    分期
    未注明
    开始
    2019-11
    登记号
    NCT04454892

    年龄未注明(登记的条件)

    牵头:北京大学第三医院北京

  3. 正在招募
    A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
    分期
    II/III期
    开始
    2025-10
    登记号
    NCT07082192

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  4. 正在招募
    The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
    分期
    I期
    开始
    2025-09
    登记号
    NCT07118319

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科眼科/神经眼科
牵头的论文52
  1. A rare genetic variant in APEX1 is associated with familial amyotrophic lateral sclerosis with slow progression.2025Acta neurologica Belgica
  2. Educational adjustments for the Chinese version of the Edinburgh Cognitive and Behavioral Screen (ECAS): establishing normative data.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. The contralateral co-movement test in a Chinese population with amyotrophic lateral sclerosis.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  4. Low CD3 level is a risk factor for amyotrophic lateral sclerosis: a Mendelian randomization study.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  5. Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.2025Annals of medicine
  6. Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.2025JAMA network openRCT
  7. Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis.2025Journal of neurology
  8. Characteristics of Neuromuscular Ultrasound in Patients with Amyotrophic Lateral Sclerosis.2025Neuro-degenerative diseases
  9. Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.2025Neurodegenerative disease management
  10. Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  11. Two-step Mendelian randomization reveals a lipid-driven protective effect of type 2 diabetes on ALS.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Concomitant presence of a novel ARPP21 variant and CNVs in Chinese familial amyotrophic lateral sclerosis-frontotemporal dementia patients.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  13. Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.2025Revista de neurologia
  14. The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study.2025Scientific reports
  15. Smell loss is associated with cognitive impairment in amyotrophic lateral sclerosis patients.2024CNS neuroscience & therapeutics
  16. Immune-mediated diseases are associated with a higher risk of ALS incidence: a prospective cohort study from the UK Biobank.2024Frontiers in immunology
  17. Whole-Genome Sequencing Identified a Novel Mutation in the N-Terminal Domain of KIF5A in Chinese Patients with Familial Amyotrophic Lateral Sclerosis.2024Genes
  18. Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.2024Orphanet journal of rare diseases
  19. Lower creatinine-to-cystatin c ratio associated with increased risk of incident amyotrophic lateral sclerosis in the prospective UK biobank cohort.2024Scientific reports
  20. The integrity of the corticospinal tract and corpus callosum, and the risk of ALS: univariable and multivariable Mendelian randomization.2024Scientific reports
  21. Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.2023Annals of neurology
  22. Cost analysis of amyotrophic lateral-sclerosis management in China.2023Asian journal of surgery
  23. Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.2023European journal of neurology
  24. Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis.2023European journal of neurology
  25. Neutrophils: a subgroup of neglected immune cells in ALS.2023Frontiers in immunology
  26. A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  27. An identical DCTN1 mutation in two Chinese siblings manifest as dHMN and ALS respectively: a case report.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  28. Human endogenous retrovirus K (HERV-K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  29. Assessment of bidirectional relationships between 98 genera of the human gut microbiota and amyotrophic lateral sclerosis: a 2-sample Mendelian randomization study.2022BMC neurology
  30. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.2022Journal of neurology
  31. Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis.2022Neurological research
  32. Dietary-Derived Essential Nutrients and Amyotrophic Lateral Sclerosis: A Two-Sample Mendelian Randomization Study.2022Nutrients
  33. Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study.2022Orphanet journal of rare diseases
  34. Small fiber neuropathy for assessment of disease severity in amyotrophic lateral sclerosis: corneal confocal microscopy findings.2022Orphanet journal of rare diseases
  35. Association between type 2 diabetes and amyotrophic lateral sclerosis.2022Scientific reports
  36. Amyotrophic lateral sclerosis: new era, new challenges.2022The Lancet. Neurology
  37. Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis.2021BMC neurology
  38. Induced pluripotent stem cell-derived motor neurons from amyotrophic lateral sclerosis (ALS) patients carrying different superoxide dismutase 1 mutations recapitulate pathological features of ALS.2021Chinese medical journal
  39. Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort.2021Chinese medical journal
  40. Trends in the clinical features of amyotrophic lateral sclerosis: A 14-year Chinese cohort study.2021European journal of neurology
  41. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.2021European journal of neurology
  42. Daytime sleepiness might increase the risk of ALS: a 2-sample Mendelian randomization study.2021Journal of neurology
  43. Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis.2021Neurobiology of aging
  44. Physical activity and amyotrophic lateral sclerosis: a Mendelian randomization study.2021Neurobiology of aging
  45. GLT8D1 may not be significant in Chinese sporadic amyotrophic lateral sclerosis patients.2021Neurobiology of aging
  46. The complement C7 variant rs3792646 is associated with amyotrophic lateral sclerosis in a Han Chinese population.2021Neurobiology of aging
  47. TBK1 variants in Chinese patients with amyotrophic lateral sclerosis.2021Neurobiology of aging
  48. Leukocyte telomere length and amyotrophic lateral sclerosis: a Mendelian randomization study.2021Orphanet journal of rare diseases
  49. Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.2021PloS one
  50. Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression.2021Scientific reports
  51. Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?2021The International journal of neuroscience
  52. A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.2021Translational neurodegeneration
中文论文(未计入)7
  1. [Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis].2023Zhonghua nei ke za zhi
  2. [Cortical thickness and cognitive impairment in patients with amyotrophic lateral sclerosis].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  3. [Genetic distribution in Chinese patients with hereditary peripheral neuropathy].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  4. [Cu/Zn superoxide dismutase and amyotrophic lateral sclerosis: a review of the current state of basic research and clinical trials].2022Zhonghua nei ke za zhi
  5. [Corneal confocal microscopy detects small-fiber neuropathy in patients with amyotrophic lateral sclerosis].2022Zhonghua nei ke za zhi
  6. [Rare variants of HSPB1 are probably associated with amyotrophic lateral sclerosis].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. [Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].2021Zhonghua yi xue za zhi
早期论文(2016–2020 年)36
  1. The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Twelve-month duration as an appropriate criterion for flail arm syndrome.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study.2020Annals of clinical and translational neurology
  4. Reply to "Life Course Adiposity and Amyotrophic Lateral Sclerosis".2020Annals of neurology
  5. Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.2020Annals of neurology
  6. Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol.2020BMJ open
  7. Anesthetic management of a parturient with amyotrophic lateral sclerosis undergoing cesarean section.2020Chinese medical journal
  8. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study.2020Journal of neurology, neurosurgery, and psychiatry
  9. Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2.2020Journal of neurology, neurosurgery, and psychiatry
  10. Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  11. Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.2020Scientific reports
  12. [Decremental responses to repetitive nerve stimulation at slow rates in amyotrophic lateral sclerosis].2020Zhonghua nei ke za zhi
  13. Cognitive and behavioral impairments in German and Chinese ALS populations - a post-hoc comparison of national study data.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  14. Vestibular evoked myogenic potentials and their clinical utility in patients with amyotrophic lateral sclerosis.2019Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  15. Two rare variants of the ANXA11 gene identified in Chinese patients with amyotrophic lateral sclerosis.2019Neurobiology of aging
  16. [Application value of motor unit number index in patients with amyotrophic lateral sclerosis].2019Zhonghua yi xue za zhi
  17. Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.2018Amyotrophic lateral sclerosis & frontotemporal degeneration
  18. Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015.2018Brain and behavior
  19. The epidemiology and genetics of Amyotrophic lateral sclerosis in China.2018Brain research
  20. Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis.2018Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  21. Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS.2018Journal of neurology, neurosurgery, and psychiatry
  22. Using the Capture-Recapture Method to Estimate the Incidence of Amyotrophic Lateral Sclerosis in Beijing, China.2018Neuroepidemiology
  23. A novel mutation of BICD2 gene associated with juvenile amyotrophic lateral sclerosis.2017Amyotrophic lateral sclerosis & frontotemporal degeneration
  24. Clinical Features of Isolated Bulbar Palsy of Amyotrophic Lateral Sclerosis in Chinese Population.2017Chinese medical journal
  25. Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention.2017Chinese medical journal
  26. Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese.2017Genome medicine
  27. CHCHD10 mutations in patients with amyotrophic lateral sclerosis in Mainland China.2017Neurobiology of aging
  28. DCTN1 gene analysis in Chinese patients with sporadic amyotrophic lateral sclerosis.2017PloS one
  29. No Evidence for Pathogenic Role of UBQLN2 Mutations in Sporadic Amyotrophic Lateral Sclerosis in the Mainland Chinese Population.2017PloS one
  30. Association Between Rectus Abdominis Denervation and Ventilation Dysfunction in Patients with Amyotrophic Lateral Sclerosis.2016Chinese medical journal
  31. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.2016Chinese medical journal
  32. MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis.2016Neurobiology of aging
  33. Two distinct clinical features and cognitive impairment in amyotrophic lateral sclerosis patients with TARDBP gene mutations in the Chinese population.2016Neurobiology of aging
  34. The presence of spontaneous EMG activity in sternocleidomastoid is associated with ventilatory dysfunction in ALS.2016Neurophysiologie clinique = Clinical neurophysiology
  35. The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese Amyotrophic Lateral Sclerosis Population.2016PloS one
  36. [Association of serum uric acid level with amyotrophic lateral sclerosis].2016Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients正在招募NCT05923905牵头方IV期2023-01 启动
  2. Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)正在招募NCT04454892牵头方2019-11 启动
  3. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis即将招募NCT06645197牵头方早期I期2024-10 启动
  4. Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis状态不明NCT04953494牵头方2021-08 启动
  5. Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis状态不明NCT04953481牵头方2021-01 启动
  6. Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China邀请入组NCT04961450牵头方2021-06 启动
  7. Sleep Disorders and the Onset and Progression of ALS状态不明NCT04952038牵头方2020-08 启动
  8. Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome状态不明NCT04952155牵头方II期2020-01 启动
  9. Appetite and Related Factors in Patients With ALS状态不明NCT04953624牵头方2020-08 启动
  10. Investigation on Home Care Needs of ALS Patients and Their Caregivers已完成NCT04950231牵头方2020-09 启动
  11. Efficacy and Safety of Nitrazine in the Treatment of ALS状态不明NCT04950647牵头方II期2020-07 启动
  12. Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China状态不明NCT04328675牵头方2020-03 启动
  13. The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules状态不明NCT04950933牵头方II/III期2020-06 启动
  14. Multimodal Brain Imaging Study状态不明NCT04960540牵头方2019-08 启动
  15. Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis已完成NCT04948346牵头方2018-01 启动
  16. Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases状态不明NCT04956822牵头方2018-06 启动
  17. Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis已完成NCT04455542牵头方2017-08 启动
  18. Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis已完成NCT04454840牵头方早期I期2016-05 启动
  19. Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis已完成NCT04952025牵头方2015-01 启动
  20. A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)状态不明NCT01935518牵头方II期2013-09 启动
  21. A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)进行中,不再招募NCT07223723牵头方(推断)IV期2025-12 启动
  22. A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)正在招募NCT07082192研究中心II/III期2025-10 启动
  23. The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis正在招募NCT07118319研究中心I期2025-09 启动
  24. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS即将招募NCT07169175研究中心I/II期2025-12 启动
  25. Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis进行中,不再招募NCT06493279研究中心I期2024-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07822711

    年龄 6 岁 至 12 岁(登记的条件)

    牵头:北京大学第三医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)3
  1. [Midterm clinical outcomes and radiological results of surgical treatment for Hirayama disease].2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. [Investigation of the compliance of cervical collar therapy in 73 patients with Hirayama disease].2016Zhonghua yi xue za zhi
  3. [Correlation of pre-operative factors with the outcome of surgical treatment of Hirayama disease].2016Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA正在招募NCT07822711牵头方不分期2026-10 启动
  2. Robot-assisted Training已完成NCT06648486牵头方不分期2025-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 11 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Mutation analysis of the GLA gene in Chinese patients with intracerebral hemorrhage.2021Neurobiology of aging
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. IgA expressed by glomerular mesangial cells is involved in the pathogenesis of IgA nephropathy.2025Frontiers in immunology
中文论文(未计入)1
  1. [Changes of gut microflora in newly diagnosed IgA nephropathy patients and its correlation with clinical risk factors].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
早期论文(2016–2020 年)1
  1. Expression of immunoglobulin A in human mesangial cells and its effects on cell apoptosis and adhesion.2018Molecular medicine reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  2. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Dysregulation of Circulating Tfr/Tfh Ratio in Primary biliary cholangitis.2017Scandinavian journal of immunology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinical and molecular characteristics of a child with familial adenomatous polyposis].2016Zhonghua er ke za zhi = Chinese journal of pediatrics

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

北京大学第三医院

Peking University Third Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Peking University Third Hospital Cancer Center; Peking University Third Hospital (L.S.); Beijing Haidian Section of Peking University Third Hospital; PKU 3rd People's Hospital; PUTH; Sanyuan Hospital

提出更正下载数据